More stories
Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD,...
On Monday, the day FDA’s Considerations for Potential Future Therapeutic Use of Psychedelic Drugs public comment period closed, the agency issued a request for...
Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health
Kenneth Tupper joins Joe Moore for a wide-ranging conversation on harm reduction, drug education, British Columbia’s toxic drug crisis, ayahuasca policy, entheogenic education, and...
Weekly Psychedelic Policy Briefing: October 5, 2026
A DEA judge has paused the hearing on moving all marijuana to Schedule III while he decides whether to admit a GAO report on...
Psychedelic Churches Need Psychedelic Seminaries
The psychedelic field has built institutions for studying molecules, delivering therapies, and training facilitators. Paul Ryder, founder of the Congregation for Sacred Practices, argues...
Tell the FDA What Psychedelic Care Should Look Like. You Have Until Monday.
A veteran's recovery from 10-out-of-10 pain shows what the agency's psychiatric model misses, and why your experience belongs in the record.
The post Tell the...
When Psychedelic Experiences Turn into Crisis, Training Can Make All the Difference
Most psychedelic experiences pass without incident, but when one turns into a crisis, the people who respond are usually EMS crews, emergency department staff,...
Weekly Psychedelic Policy Briefing: September 30th, 2026
DEA proposed placing five tryptamines in Schedule I, including the active compound in a postpartum depression drug FDA designated a breakthrough therapy in February....
Quarterly Psychedelics Briefing: Q3 2026
Welcome to our Q3 2026 Quarterly Briefing. Every three months, our Founder & Editor Josh Hardman walks you through major developments from the prior...
Weekly Psychedelic Policy Briefing, September 21, 2026
The FDA heard 80 speakers on the future of psychedelic drugs, and its federal panel asked none of them a question. The American Legion...
Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets Botanical Drug Exclusivity
Optimi Health has Health Canada authorization for a Phase 2 trial of natural psilocybin in up to 200 adults with major depressive disorder. Dosing...
Most popular
How to Get DMT: Obtaining the Spirit Molecule
DMT, or N,N-dimethyltryptamine, is known to be one of the world’s most powerful psychedelics. It is capable of producing experiences with intensity and profundity...
Having Sex on DMT: What You Need to Know
For those of you who have dived into the wonders of DMT, you may be investigating this article to see how sex on DMT...
DMT Pricing Guide
Smoking or vaping DMT can be a life-changing experience. The hallucinogenic compound is gaining more popularity in the world of mainstream psychedelics. But without...
William Leonard Pickard participating in celebration for Sasha Shulgin’s new book ‘The Nature of...
A Celebration of the Pioneering Legacy of Sasha and Ann Shulgin
Saturday June 26 and Sunday June 27, 2021
This is a virtual symposium which will...
PTSF49 – MDMA For Alcoholism, The Placebo Effect, and Ceremonial Magicians
In today’s Solidarity Fridays episode, Kyle, Joe, and Michelle once again meet through the airwaves to discuss recent news articles and see where that...
